PubMed COVID-19 Clinical Care

No abstract

The COVID-19 pandemic has changed the way to manage the emergencies, as people faced fear of the hospitals, with possible delay in the diagnosis. Moreover, clinicians had to rearrange protocols for diagnosis and treatment. We aimed to assess whether

To precisely determine the severity of COVID-19-related pneumonia, computed tomography (CT) is an imaging modality beneficial for patient monitoring and therapy planning. Thus, we aimed to develop a deep learning-based image segmentation model to

CONCLUSIONS: To improve patient accessibility, NSCIR-IR should take measures during data gathering to increase the accuracy of registered contact information. Regarding the loss to follow-ups of SCI patients, NSCIR-IR should find strategies for

CONCLUSION: Endothelial parameters changed more than the changes in corneal curvature and ocular biometric measurements after mild COVID-19. The decrease in endothelial cell number and hexagonality and increase in polymorphism after COVID-19 were

CONCLUSION: Vascular biomarkers, mostly VCAM-1 and Ang-2/Ang-1 ratio, showed better efficiency to predict need for hemodialysis in critically-ill COVID-19 patients.

The pandemic caused by the SARS-CoV-2 coronavirus has been especially detrimental to patients with end-stage renal disease. History with other vaccines suggests that patients with renal disease may not respond adequately to the SARS-CoV-2 vaccine

CONCLUSION: The study jointly models mixed types of outcomes in the context of developing ITRs. By considering multiple health outcomes, the proposed approach can advance the development of more effective and reliable personalized treatment.

We investigate a mathematical system of the recent COVID-19 disease focusing particularly on the transmissibility of individuals with different types of signs under the Caputo fractional derivative. To get the approximate solutions of the fractional

CONCLUSION: These findings suggest BNT162b2 booster vaccination enhanced humoral immunity to SARS-CoV-2 from pre-booster levels, and that this antibody response was detectable by the LFIA. In combination with cross-reactivity, standards and genetic